Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets

Immunobiology

Volumn 216, Issue 12, 2011, Pages 1256-1263

  Aravena, Octavio ^a   Pesce, Bárbara ^a   Soto, Lilian ^b   Orrego, Natalia ^a   Sabugo, Francisca ^b   Wurmann, Pamela ^b   Molina, María Carmen ^a   Alfaro, Jorge ^b   Cuchacovich, Miguel ^b   Aguillón, Juan Carlos ^a   Catalán, Diego ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Anti TNF; NK cells; Regulatory T cells; Rheumatoid arthritis; Th17 cells

Indexed keywords

ADALIMUMAB; GAMMA INTERFERON;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD4+ TH1 CELL; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CELL COUNT; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054961014     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.07.006     Document Type: Article

References (48)

1. Aerts N.E., De Knop K.J., Leysen J., Ebo D.G., Bridts C.H., Weyler J.J., Stevens W.J., De Clerck L.S. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 2010, 49:2264-2272.
2. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
3. Aramaki T., Ida H., Izumi Y., Fujikawa K., Huang M., Arima K., Tamai M., Kamachi M., Nakamura H., Kawakami A., Origuchi T., Matsuoka N., Eguchi K. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod. Rheumatol. 2009, 19:245-252.
4. Badot V., Galant C., Nzeusseu Toukap A., Theate I., Maudoux A.L., Van den Eynde B.J., Durez P., Houssiau F.A., Lauwerys B.R. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res. Ther. 2009, 11:R57.
5. Baldwin H.M., Ito-Ihara T., Isaacs J.D., Hilkens C.M. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:1200-1207.
6. Berg L., Lampa J., Rogberg S., van Vollenhoven R., Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann. Rheum. Dis. 2001, 60:133-139.
7. Berner B., Akca D., Jung T., Muller G.A., Reuss-Borst M.A. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J. Rheumatol. 2000, 27:1128-1135.
8. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
9. Cope A.P., Liblau R.S., Yang X.D., Congia M., Laudanna C., Schreiber R.D., Probert L., Kollias G., McDevitt H.O. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 1997, 185:1573-1584.
10. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., Breedveld F.C., Smolen J.S., Eberl G., deWoody K., Feldmann M., Maini R.N. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 1999, 163:1521-1528.
11. Chaudhry A., Rudra D., Treuting P., Samstein R.M., Liang Y., Kas A., Rudensky A.Y. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
12. Chu C.Q., Swart D., Alcorn D., Tocker J., Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 2007, 56:1145-1151.
13. Dai S.M., Shan Z.Z., Xu H., Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:1411-1418.
14. Dalbeth N., Callan M.F. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 2002, 46:1763-1772.
15. Doodes P.D., Cao Y., Hamel K.M., Wang Y., Farkas B., Iwakura Y., Finnegan A. Development of proteoglycan-induced arthritis is independent of IL-17. J. Immunol. 2008, 181:329-337.
16. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
17. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004, 200:277-285.
18. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
19. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., Ohsugi Y., Nishikawa T., Ripley B., Kimura A., Kishimoto T., Naka T. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008, 58:3710-3719.
20. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
21. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., Verreck F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 2006, 36:661-670.
22. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., Nojima Y. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 2005, 52:1037-1046.
23. Irmler I.M., Gajda M., Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J. Immunol. 2007, 179:6228-6236.
24. Jewett A., Cavalcanti M., Bonavida B. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J. Immunol. 1997, 159:4815-4822.
25. Kageyama Y., Ichikawa T., Nagafusa T., Torikai E., Shimazu M., Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol. Int. 2007, 28:137-143.
26. Kawashima M., Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann. Rheum. Dis. 2005, 64:415-418.
27. Kelchtermans H., Schurgers E., Geboes L., Mitera T., Van Damme J., Van Snick J., Uyttenhove C., Matthys P. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res. Ther. 2009, 11:R122.
28. Lexberg M.H., Taubner A., Albrecht I., Lepenies I., Richter A., Kamradt T., Radbruch A., Chang H.D. IFN-gamma and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur. J. Immunol. 2010, 40:3017-3027.
29. Lo C.K., Lam Q.L., Sun L., Wang S., Ko K.H., Xu H., Wu C.Y., Zheng B.J., Lu L. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum. 2008, 58:2700-2711.
30. Masuko-Hongo K., Sekine T., Ueda S., Kobata T., Yamamoto K., Nishioka K., Kato T. Long-term persistent accumulation of CD8+ T cells in synovial fluid of rheumatoid arthritis. Ann. Rheum. Dis. 1997, 56:613-621.
31. Maurice M.M., van der Graaff W.L., Leow A., Breedveld F.C., van Lier R.A., Verweij C.L. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42:2166-2173.
32. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198:1951-1957.
33. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 2007, 204:33-39.
34. Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63:681-687.
35. Nistala K., Adams S., Cambrook H., Ursu S., Olivito B., de Jager W., Evans J.G., Cimaz R., Bajaj-Elliott M., Wedderburn L.R. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14751-14756.
36. Romagnani S. Human Th17 cells. Arthritis Res. Ther. 2008, 10:206.
37. Sarkar S., Cooney L.A., White P., Dunlop D.B., Endres J., Jorns J.M., Wasco M.J., Fox D.A. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res. Ther. 2009, 11:R158.
38. Schuerwegh A.J., Van Offel J.F., Stevens W.J., Bridts C.H., De Clerck L.S. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003, 42:541-548.
39. Schulze-Koops H., Kalden J.R. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2001, 15:677-691.
40. Shen H., Xia L., Lu J., Xiao W. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J. Investig. Med. 2010, 58:905-908.
41. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
42. Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108:253-261.
43. Xu L., Kitani A., Fuss I., Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J. Immunol. 2007, 178:6725-6729.
44. Yamada H., Nakashima Y., Okazaki K., Mawatari T., Fukushi J.I., Kaibara N., Hori A., Iwamoto Y., Yoshikai Y. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67:1299-1304.
45. Yoshimoto T., Takeda K., Tanaka T., Ohkusu K., Kashiwamura S., Okamura H., Akira S., Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J. Immunol. 1998, 161:3400-3407.
46. Yue C., You X., Zhao L., Wang H., Tang F., Zhang F., Zhang X., He W. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol. Int. 2010, 30:1553-1557.
47. Zou J., Rudwaleit M., Brandt J., Thiel A., Braun J., Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum. 2003, 48:780-790.
48. Zou J., Rudwaleit M., Brandt J., Thiel A., Braun J., Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann. Rheum. Dis. 2003, 62:561-564.